Literature DB >> 10073146

Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.

K Shimozuma1, H Sonoo, M Fukunaga, K Ichihara, T Aoyama, K Tanaka.   

Abstract

BACKGROUND: Some biochemical markers of bone turnover are expected to reflect the disease activity of metastatic bone tumor. In the present study six biochemical markers were evaluated to determine appropriate markers for the detection of metastatic bone tumors from breast cancer (BC).
METHODS: A panel of bone turnover markers was assessed in 11 normocalcemic patients with bone metastases from BC and in 19 BC patients without clinical evidence of bone metastases. Bone formation was investigated by measuring serum bone isoenzyme of alkaline phosphatase (BALP), osteocalcin (OC) and carboxy-terminal propeptide of type I procollagen (PICP): Bone resorption was investigated by measuring serum carboxy-terminal telopeptide of type I collagen (ICTP), fasting urinary pyridinoline (Pyr) and deoxypyridinoline (D-Pyr).
RESULTS: PICP was influenced by age and menopausal status. Significant correlations were observed between each of bone turnover markers except between BALP and OC. The mean levels of the six bone turnover markers were higher in patients with bone metastases than in those without them and significance was observed except for OC. The best diagnostic efficiency by receiver-operating characteristic (ROC) analysis was provided by ICTP followed by Pyr or D-Pyr, BALP, PICP and OC and significance was observed between ICTP and OC. Multiple logistic regression analysis adjusted by age revealed that the only significant marker related to bone metastases was ICTP.
CONCLUSIONS: Serum ICTP appears to be the leading marker of bone metastases from BC. However, to reveal the clinical usefulness of these markers, further examination will be needed to account for the ease and cost-effectiveness of the measurements.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073146     DOI: 10.1093/jjco/29.1.16

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  5 in total

1.  Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases.

Authors:  Athanasios Zafeirakis; Georgios Papatheodorou; Athanasios Arhontakis; Athanasios Gouliamos; Lambros Vlahos; Georgios S Limouris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

2.  Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.

Authors:  Song Yao; Yali Zhang; Li Tang; Janise M Roh; Cecile A Laurent; Chi-Chen Hong; Theresa Hahn; Joan C Lo; Christine B Ambrosone; Lawrence H Kushi; Marilyn L Kwan
Journal:  Breast Cancer Res Treat       Date:  2016-12-03       Impact factor: 4.872

Review 3.  Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.

Authors:  Robert Coleman; Janet Brown; Evangelos Terpos; Allan Lipton; Matthew R Smith; Richard Cook; Pierre Major
Journal:  Cancer Treat Rev       Date:  2008-06-24       Impact factor: 12.111

4.  Uncarboxylated osteocalcin promotes proliferation and metastasis of MDA-MB-231 cells through TGF-β/SMAD3 signaling pathway.

Authors:  Jiaojiao Xu; Luyao Ma; Danqing Wang; Jianhong Yang
Journal:  BMC Mol Cell Biol       Date:  2022-04-12

Review 5.  Mechanisms, Diagnosis and Treatment of Bone Metastases.

Authors:  Jozef Ban; Valerie Fock; Dave N T Aryee; Heinrich Kovar
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.